Market capitalization | €9.23b |
Enterprise Value | €9.70b |
P/E (TTM) P/E ratio | 145.45 |
EV/FCF (TTM) EV/FCF | 25.16 |
EV/Sales (TTM) EV/Sales | 5.41 |
P/S ratio (TTM) P/S ratio | 5.14 |
P/B ratio (TTM) P/B ratio | 2.91 |
Revenue growth (TTM) Revenue growth | -5.12% |
Revenue (TTM) Revenue | €1.79b |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
20 Analysts have issued a Qiagen forecast:
20 Analysts have issued a Qiagen forecast:
Dec '23 | |
Current assets | 1,944 1,944 |
Fixed assets | 3,592 3,592 |
Total Assets | 5,536 5,536 |
Dec '23 | |
Equity | 3,447 3,447 |
Debt capital | 2,089 2,089 |
Total Capital | 5,536 5,536 |
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Head office | United States |
CEO | Thierry Bernard |
Employees | 5,967 |
Founded | 1996 |
Website | www.qiagen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.